Oncology Based Molecular Diagnostics Market - By Product Type (Instruments, Reagents & Kits), Technology (PCR, INAAT, Sequencing, In-situ Hybridization, Chips & Microarrays, Mass Spectrometry), Application, End-use - Global Forecast (2024 - 2032)
Description
Oncology Based Molecular Diagnostics Market - By Product Type (Instruments, Reagents & Kits), Technology (PCR, INAAT, Sequencing, In-situ Hybridization, Chips & Microarrays, Mass Spectrometry), Application, End-use - Global Forecast (2024 - 2032)
Global Oncology Based Molecular Diagnostics Market size will record 4.6% CAGR from 2024 to 2032, driven by technology strides, such as next-generation sequencing and advanced PCR systems. These innovations are enhancing the precision and speed of cancer detection, further driving the demand for molecular tests. Moreover, the trend of personalized medicine will fuel the market growth, as molecular diagnostics enable the identification of specific genetic markers and mutations for tailored treatment plans. This convergence of technology and personalized healthcare will improve patient outcomes for shaping the future of cancer care. For instance, in November 2023, Roche introduced the LightCycler® PRO System, a next-gen qPCR system, to meet clinical needs in molecular diagnostics and tackle public health challenges effectively.
The oncology based molecular diagnostics market is segmented on the basis of product type, technology, application, end use, and region.
By end use, the industry size from the diagnostic laboratories segment will capture considerable share by 2032 due to the increasing demand for precise and early cancer detection, coupled with the advanced technologies housed in these facilities. Diagnostic laboratories offer a comprehensive range of molecular tests for providing clinicians with crucial insights for personalized treatment plans. Moreover, these settings are equipped with established infrastructure and skilled personnel to ensure efficient and accurate results.
In terms of application, the oncology based molecular diagnostics industry from the blood cancer segment will accumulate remarkable gains through 2032. The rising incidence of blood cancers globally is necessitating accurate and timely diagnostic solutions. Molecular diagnostics play a pivotal role in identifying specific genetic markers and mutations crucial for blood cancer diagnosis and treatment planning. With advancements in technology facilitating more precise and sensitive testing, the segment will see substantial growth.
Europe oncology based molecular diagnostics market will demonstrate a substantial CAGR from 2024 to 2032. This can be attributed to a robust healthcare infrastructure, widespread adoption of advanced diagnostic technologies, and proactive government initiatives promoting cancer research and treatment. With the focus on precision medicine and personalized cancer care, European countries are increasingly implementing molecular diagnostic solutions. This The emphasis on more effective and targeted cancer management strategies will also contribute to the regional industry growth.
Table of Contents
186 Pages
- Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Base estimates & calculations
- 1.3 Data collection
- 1.4 Forecast parameters
- 1.5 Data validation
- 1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
- 1.6.2.1 Paid sources
- 1.6.2.2 Public sources
- Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
- Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of cancer worldwide
- 3.2.1.2 Technological advancements in molecular diagnostics
- 3.2.1.3 Growing demand for personalized medicine
- 3.2.1.4 Rising demand for point-of-care testing
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Stringent regulatory scenario
- 3.2.2.2 High cost of molecular diagnostics
- 3.3 Growth potential analysis
- 3.4 Technological landscape
- 3.5 Regulatory landscape
- 3.6 Porter's analysis
- 3.6.1 Supplier power
- 3.6.2 Buyer power
- 3.6.3 Threat of new entrants
- 3.6.4 Threat of substitutes
- 3.6.5 Industry rivalry
- 3.7 PESTEL analysis
- Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive positioning matrix
- 4.4 Strategy outlook matrix
- Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Instruments
- 5.3 Reagents and kits
- 5.4 Other product types
- Chapter 6 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Polymerase chain reaction (PCR)
- 6.3 Isothermal nucleic acid amplification technology (INAAT)
- 6.4 Sequencing
- 6.5 In-situ hybridization
- 6.6 Chips and microarrays
- 6.7 Mass spectrometry
- 6.8 Other technologies
- Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Breast cancer
- 7.3 Prostate cancer
- 7.4 Colorectal cancer
- 7.5 Cervical cancer
- 7.6 Liver cancer
- 7.7 Lung cancer
- 7.8 Blood cancer
- 7.9 Kidney cancer
- 7.10 Other applications
- Chapter 8 Market Estimates and Forecast, By End-use, 2018 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospitals and clinics
- 8.3 Diagnostic laboratories
- 8.4 Other end-users
- Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
- Chapter 10 Company Profiles
- 10.1 Abbott Laboratories
- 10.2 Agilent Technologies, Inc.
- 10.3 Becton, Dickinson and Company
- 10.4 Biocartis Group NV
- 10.5 bioMerieux S.A.
- 10.6 Bio-Rad Laboratories, Inc.
- 10.7 Danaher Corporation
- 10.8 F. Hoffmann La Roche Ltd.
- 10.9 Hologic, Inc.
- 10.10 Illumina, Inc.
- 10.11 QIAGEN N.V.
- 10.12 Siemens Healthineers AG
- 10.13 Sysmex Corporation
- 10.14 Thermo Fisher Scientific Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
